Dementia monitoring tools are made safer through clear risk tiers, prescription controls, and required clinical testing. Low-risk trackers stay as wellness products, while software that predicts dementia faces medical-device review. Dementia monitoring tools means software that tracks memory, thinking, sleep, activity, or test results to flag change. The new approach sorts products by risk, then applies matching safeguards for accuracy, labeling, and follow-up.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official guidance from FDA — Use this primary source to verify the official guidance.
- Read the official guidance from FDA — Use this primary source to verify the official guidance.
Table of Contents
- Which brain-health products stay wellness products?
- When can clinician software offer dementia advice?
- What safety checks apply to MCI prognosis software?
- What should families check before trusting a result?
- How do tools stay safe after updates?
Which brain-health products stay wellness products?
Passive wearables that report focus, sleep, or heart rate can remain wellness products. Software that claims to detect cognitive decline is treated as a medical device needing review, according to Inside BCI reporting on the January 2026 update Inside BCI analysis. FDA reissued final General Wellness guidance for low-risk devices on January 6, 2026, adding clarity for products with noninvasive sensing, as listed on the FDA wellness guidance page.
The line turns on claims and risk, not on whether the product uses a phone or watch. A memory-boost headband is not low-risk wellness if it uses electrical stimulation. FDA states such neurostimulation needs medical-device oversight because stimulation brings safety risks unlike passive tracking.
When can clinician software offer dementia advice?
FDA issued final Clinical Decision Support Software guidance on January 6, 2026 and reissued it January 29, 2026 to explain which clinician tools fall outside the device definition under section 520(o)(1)(E), as listed on the FDA decision-support page. That sorting helps clinics know which tools need device controls. The January 2026 update allows enforcement discretion for AI tools that give a single clinical recommendation when developers disclose reasoning so clinicians can check it independently.
In practice, the doctor must be able to see the basis, weigh it against exams and history, and reach the same decision without blind trust. For families, the test is simple. Ask whether the output guides the clinician or replaces judgment. Tools that explain their inputs support safer review, while black-box answers deserve more caution.
What safety checks apply to MCI prognosis software?
In a final order effective November 5, 2026, FDA placed prognostic assessment software for mild cognitive impairment into Class II under 21 CFR 882.1454, applicable back to January 11, 2024. That move set a fixed product code and review route for later products of the same type. The classified device is prescription-only and combines several clinical sources such as imaging, demographics, and test scores.
It outputs likelihood of progression to severe impairment or dementia such as Alzheimer's, for adjunctive use only and not as a standalone diagnosis. FDA imposed special controls for wrong analysis or device failure, including premarket clinical validation, sensitivity and specificity and predictive-value reporting, limits disclosure, physician and patient labeling, human-factors testing, and postmarket surveillance, as summarized by Health Newspapers in its report on the order. Later devices of the same type may use the 510(k) pathway by showing substantial equivalence plus those controls.
What should families check before trusting a result?
Bring the full medication list, sleep history, hearing and vision issues, and prior test scores to the visit. Those factors can mimic memory decline and change what a score means.
Ask how the clinic will act on high, low, and uncertain results. A clear follow-up plan matters more than a single percentage.
- Prescription status: prediction tools for mild cognitive impairment require a clinician order.
- Intended use: adjunctive risk estimate, not a diagnosis of Alzheimer's on its own.
- Inputs: imaging, test scores, and history together, not one phone quiz.
- Label limits: accuracy numbers, false-result risks, and when to seek full evaluation.
How do tools stay safe after updates?
FDA lists complementary lifecycle safeguards including final guidance on predetermined change-control plans for AI-enabled functions dated August 18, 2025 and draft lifecycle-management guidance dated January 7, 2025, plus final December 22, 2023 guidance on remote data collection in trials. Together they cover planned AI changes, ongoing monitoring, and valid trial data from home devices.
For readers, that means approved tools should describe allowed updates and continued performance checks. If a vendor cannot explain what changed in a new version, ask the prescribing clinician whether the result still applies.





